Updated PFS with Isa-Kd vs Kd (ITT population).
CI confidence interval, d dexamethasone, HR hazard ratio, Isa isatuximab, ITT intent to treat, K carfilzomib, mPFS median progression-free survival.To evaluate the robustness of the primary analysis, PFS sensitivity analyses using different censoring rules, as per IRC and per investigator assessment, were also updated (Supplementary Table As presented in Fig. 